Alexandria Venture Investments, LLC v. Verseau Therapeutics, Inc.

CourtCourt of Chancery of Delaware
DecidedDecember 18, 2020
DocketC.A. No. 2020-0593-PAF
StatusPublished

This text of Alexandria Venture Investments, LLC v. Verseau Therapeutics, Inc. (Alexandria Venture Investments, LLC v. Verseau Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Alexandria Venture Investments, LLC v. Verseau Therapeutics, Inc., (Del. Ct. App. 2020).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ) ALEXANDRIA VENTURE ) INVESTMENTS, LLC and ) ALEXANDRIA EQUITIES NO. 7, ) LLC, ) ) Plaintiffs, ) ) v. ) C.A. No. 2020-0593-PAF ) VERSEAU THERAPEUTICS, INC., ) ) Defendant. ) )

MEMORANDUM OPINION

Date Submitted: October 1, 2020 Date Decided: December 18, 2020

Raymond J. DiCamillo, Megan E. O’Connor, RICHARDS, LAYTON & FINGER, P.A., Wilmington, Delaware; Luke Cadigan, COOLEY LLP, Boston, Massachusetts; Patrick Gunn, COOLEY LLP, San Francisco, California; Attorneys for Plaintiffs Alexandria Venture Investments, LLC and Alexandria Equities No. 7, LLC.

David J. Teklits, Thomas P. Will, MORRIS, NICHOLS, ARSHT, & TUNNELL LLP, Wilmington, Delaware; Attorneys for Defendant Verseau Therapeutics, Inc.

FIORAVANTI, Vice Chancellor Plaintiffs Alexandria Venture Investments, LLC (“Alexandria Venture”) and

Alexandria Equities No. 7, LLC (“Alexandria Equities” and together with

Alexandria Venture, “Alexandria”) seek an order to compel inspection of books and

records of Verseau Therapeutics, Inc. (“Verseau” or the “Company”) pursuant to

Section 220 of the Delaware General Corporation Law (“DGCL”). Alexandria aims

to investigate, among other things, whether Verseau’s directors violated their

fiduciary duties when they rejected a financing proposal from Alexandria. In this

post-trial Opinion, I conclude that Alexandria is entitled to inspect some, but not all,

of the categories of books and records sought in the demand.

I. BACKGROUND

The facts recited in this Opinion are the Court’s findings based on the

testimony and documentary evidence presented at a half-day trial on October 1,

2020. The record includes stipulations of fact contained in the parties’ Pretrial

Stipulation and Order (“PTO”), the 62 trial exhibits, and deposition testimony from

one witness, Aaron Jacobson.1 The following facts were either uncontested or have

been proven by a preponderance of the evidence.

1 Citations in the form “Tr.” refer to the trial transcript. Citations in the form “JX” refer to trial exhibits with pinpoint citations to the last three digits of the relevant Bates number. Citations in the form “Dep.” refer to the Jacobson deposition transcript.

2 A. The Parties

Verseau is a privately held Delaware corporation founded in 2017 to develop

immunotherapies to treat cancer. During relevant events and at least until June 30,

2020, Verseau’s board of directors (the “Board”) consisted of seven individuals:

Christine Bunt, George Golumbeski, Zhenping Zhu, Jong Chang, Wen Chen, Bob

Langer, and Daniel Anderson. 2 Bunt was Verseau’s Chief Executive Officer during

that same time period.3 Golumbeski is the chairman of the Board, having previously

served as Executive Vice President of Business Development at Celgene

Corporation (“Celgene”), a biotechnology company.4 Golumbeski initially joined

Verseau as an advisor in 2018, and he continued to provide consulting services to

Verseau after joining the Board in 2019.5 Golumbeski owns approximately 1% of

Verseau’s stock on a fully diluted basis.6 Zhu is affiliated with 3SBio Inc.

(“3SBio”), a biotechnology company based in China, where he serves as President

of Research & Development and Chief Scientific Officer.7 3SBio owns 11.8% of

the Company’s stock.8 Chang is the founder and chairman of InHarv Partners Ltd.

2 Pretrial Stipulation and Order (“PTO”) ¶ 7. 3 Id. ¶ 8. 4 JX 14. 5 Id. 6 Tr. 72:12–17. 7 JX 4 at ‘095–96. 8 JX 62.

3 (“InHarv”), a venture capital firm, 9 which owns 24.4% of the Company’s stock.10

Langer and Anderson are co-founders of Verseau.11

Plaintiffs are venture capital firms and preferred stockholders of Verseau.12

Together, Plaintiffs own 5.1% of the Company’s stock.13 Joel Marcus is the

Executive Chairman of Alexandria Real Estate Equities, Inc., which is the managing

member of Alexandria Venture and ultimate managing member of Alexandria

Equities. 14 Aaron Jacobson is Senior Vice President and Venture Counsel of

Alexandria Real Estate Equities, Inc. 15

Marcus frequently attended Board meetings as one of Alexandria’s Board

observers. 16 At its March 13, 2020 meeting, the Board “expressed support for adding

Marcus to the Board subject to receipt of the requisite stockholder consents.” 17 The

Company subsequently informed its preferred stockholders of the Board’s decision

9 Id. at ‘095. 10 JX 62. The stock ownership reported for Golumbeski, S3Bio, InHarv, and Alexandria is on a fully diluted basis. Id. 11 PTO ¶ 7. 12 PTO ¶¶ 4–5. One or more representatives of Alexandria typically attend Board meetings. See JX 51 at ‘952, ‘958; JX 40 at ‘901, ‘909. 13 JX 62. 14 PTO ¶ 9. 15 PTO ¶ 11. 16 JX 51 at ‘952, ‘958; JX 40 at ‘901, ‘909. 17 JX 40 at ‘903.

4 to add Marcus as a director.18 The Company told stockholders that Marcus would

become a director after the stockholders agreed to expand the Board, a voting

agreement was amended, and the Board formally elected Marcus.19 There is no

evidence in the record that any of those events occurred, and I find that they did not.

B. Recent Hires at Verseau

After Golumbeski joined the Board, Verseau hired three former Celgene

employees into senior positions. In November 2019, Verseau hired Tim Smith,

Celgene’s former Executive Director of Business Development, as Verseau’s new

Chief Business Officer. 20 In February 2020, Verseau hired Alise Reicin, Celgene’s

former President of Global Clinical Development, as Veseau’s new Chief Medical

Officer.21 Verseau hired another former Celgene employee as a senior advisor that

same month. 22 Smith’s time at Celgene overlapped with Golumbeski’s, 23 but there

is no evidence in the record indicating that Golumbeski had directly worked with

Smith.24 Reicin did not overlap with Golumbeski while at Celgene. 25

18 JX 1 at ‘093. 19 Id. at ‘093–94. 20 JX 59. 21 JX 53. 22 JX 52. 23 See JX 58, 59. 24 Dep. 22:5–23:18. 25 Id.

5 C. Negotiation of the Term Sheet

In March 2020, Verseau needed cash, particularly to weather the global

pandemic. Verseau and Alexandria, an existing Verseau stockholder, then began

discussing bridge financing. On April 25, Alexandria sent to Verseau a non-binding

term sheet that generally provided for Alexandria to lead a financing round of $30

million in convertible notes.26 Among other terms, the proposal provided investors

a 2.0x return on investment in the event of a change in control. It also gave

Alexandria the right to designate a director to serve on the Board and specified

Marcus as Alexandria’s initial director designee. Bunt sent Verseau’s response a

week later, stating that the proposal was generally “a fair balance for the

company.”27 Verseau pushed back, however, on a few provisions, two of which are

pertinent to this Opinion. 28

First, the Company resisted terms giving Alexandria significant power over

Verseau’s relationship with 3SBio, where Zhu was an officer. Verseau had

partnered with 3SBio on one recent project and anticipated partnering with 3SBio

on a second project within the next year. 29 Alexandria’s initial proposal required

approval by Alexandria’s designated Board member for any related-party

26 JX 5. 27 See JX 6. 28 Id. 29 Id.

6 transaction with a value of $50,000 or more.30 Verseau was concerned that this

provision would jeopardize the Company’s plans to partner with 3SBio, and it

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Henshaw v. American Cement Corporation
252 A.2d 125 (Court of Chancery of Delaware, 1969)
In Re the Walt Disney Co. Derivative Litigation
825 A.2d 275 (Court of Chancery of Delaware, 2003)
CM & M GROUP, INC. v. Carroll
453 A.2d 788 (Supreme Court of Delaware, 1982)
Seinfeld v. Verizon Communications, Inc.
909 A.2d 117 (Supreme Court of Delaware, 2006)
Helnsman Management Services, Inc. v. a & S Consultants, Inc.
525 A.2d 160 (Court of Chancery of Delaware, 1987)
Kaufman v. CA, INC.
905 A.2d 749 (Court of Chancery of Delaware, 2006)
Saito v. McKesson HBOC, Inc.
806 A.2d 113 (Supreme Court of Delaware, 2002)
Security First Corp. v. U.S. Die Casting & Development Co.
687 A.2d 563 (Supreme Court of Delaware, 1997)
Thomas & Betts Corp. v. Leviton Manufacturing Co.
681 A.2d 1026 (Supreme Court of Delaware, 1996)
Pershing Square v. Ceridian Corporation
923 A.2d 810 (Court of Chancery of Delaware, 2007)
Highland Select Equity Fund, L.P. v. Motient Corp.
906 A.2d 156 (Court of Chancery of Delaware, 2006)
Delaware County Employees Retirement Fund v. Sanchez
124 A.3d 1017 (Supreme Court of Delaware, 2015)
Amalgamated Bank v. Yahoo! Inc.
132 A.3d 752 (Court of Chancery of Delaware, 2016)
KT4 Partners LLC v. Palantir Technologies, Inc.
203 A.3d 738 (Supreme Court of Delaware, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Alexandria Venture Investments, LLC v. Verseau Therapeutics, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/alexandria-venture-investments-llc-v-verseau-therapeutics-inc-delch-2020.